Form 4: Venrock Healthcare Capital Partners III, L.P. Increases Stake in KalVista Pharmaceuticals, Inc.

Venrock Healthcare Capital Partners III, L.P. and related entities have increased their holdings in KalVista Pharmaceuticals, Inc. through a series of open market purchases.

Summary

• Venrock Healthcare Capital Partners III, L.P., along with related entities, has reported the acquisition of additional shares of KalVista Pharmaceuticals, Inc. common stock.
• The purchases occurred over three trading days: January 30, 2025, January 31, 2025, and February 3, 2025.
• A total of 43,707 shares were purchased on January 30 at a weighted average price of $8.76 per share.
• On January 31, 11,754 shares were acquired at a weighted average price of $8.89 per share.
• Finally, on February 3, 14,562 shares were purchased at a weighted average price of $9.22 per share.
• These transactions increased the total holdings of the reporting entities to 5,012,796 shares.
• The shares are held indirectly through various funds and entities managed by Venrock.

Sentiment

Score: 7

Explanation: The document indicates increased investment by a major shareholder, which is generally a positive sign. However, it is a routine filing and does not contain any groundbreaking news.

Positives

• The increased investment by Venrock Healthcare Capital Partners III, L.P. could be seen as a positive signal of confidence in KalVista Pharmaceuticals, Inc.
• The consistent purchasing activity suggests a strong belief in the company's future prospects.

Risks

• The document does not explicitly state any risks, but the increased stake could be a risk if the company's performance does not meet expectations.
• The document does not provide any information about the reasons for the purchases, which could be a risk if the reasons are not positive.

Industry Context

This filing indicates continued investment activity in the biotechnology sector, specifically in KalVista Pharmaceuticals, Inc., which is developing treatments for rare diseases. Venrock's increased stake suggests confidence in the company's pipeline and future prospects.

Comparison to Industry Standards

• Venrock's investment in KalVista is consistent with venture capital firms' typical strategy of investing in promising biotech companies.
• The size of the investment is not unusual for a firm of Venrock's size and experience.
• The weighted average prices paid are within the range of typical market prices for a company like KalVista.
• Other comparable companies in the biotech space have seen similar investment patterns from venture capital firms.

Stakeholder Impact

• The increased stake by Venrock could be viewed positively by shareholders, potentially increasing confidence in the company.
• The transactions do not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

KalVista Pharmaceuticals, Venrock Healthcare Capital Partners, Share Acquisition, SEC Form 4, Insider Trading, Equity Investment